E. Fang

发表

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.

W. O'Riordan, P. Prokocimer, C. D. De Anda, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.

P. Tulkens, P. Prokocimer, D. Das, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

S. Flanagan, T. Marbury, P. Prokocimer, 2014, Antimicrobial Agents and Chemotherapy.

Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study.

S. Flanagan, P. Prokocimer, J. Litwin, 2016, International journal of antimicrobial agents.

Absorption, Distribution, Metabolism, and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate

S. Flanagan, Jeffrey B Locke, K. Bartizal, 2014, Drug Metabolism and Disposition.

In Vitro, In Vivo, and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase Interactions

S. Flanagan, K. Bartizal, P. Prokocimer, 2013, Antimicrobial Agents and Chemotherapy.

Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers

P. Prokocimer, E. Fang, K. Muñoz, 2017, American journal of therapeutics.

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

G. Moran, Anita F. Das, G. Corey, 2014, The Lancet. Infectious diseases.

Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections

A. Shorr, Anita F. Das, G. Corey, 2014, Antimicrobial Agents and Chemotherapy.

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Anita F. Das, P. Prokocimer, C. D. De Anda, 2013, JAMA.

DMD056697 1275..1284

S. Flanagan, Jeffrey B Locke, K. Bartizal, 2014 .

Absorption , Distribution , Metabolism , and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate s

S. Flanagan, Jeffrey B Locke, K. Bartizal, 2014 .

Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid

S. Flanagan, P. Prokocimer, S. Minassian, 2014, Pharmacotherapy.

Platelet Profile in Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid or Linezolid: Findings from the Phase 3 ESTABLISH Clinical Trials

P. Prokocimer, T. Lodise, S. Minassian, 2014, Antimicrobial Agents and Chemotherapy.

Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections

S. Flanagan, P. Prokocimer, J. Passarell, 2016, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen

J. Bulitta, B. Hafkin, E. Fang, 2021, Open Forum Infectious Diseases.

Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials

Anita F. Das, P. Prokocimer, T. Sandison, 2017, Antimicrobial Agents and Chemotherapy.